ERBB2 and breast cancer: The overexpression of STEAP4 in the HER2+ BC cells which emerged for the first time in our screening efforts, in tandem with the IHC results in the TMAs, was the inflection point which triggered us to proceed to the pharmacological evaluation of the STEAP4 in HER2+ BC models.